These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12952733)

  • 21. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
    Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
    J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi.
    Palombi L; Galluzzo CM; Pirillo MF; Liotta G; Andreotti M; Jere H; Sagno JB; Luhanga R; Mancinelli S; Ceffa S; Amici R; Marazzi MC; Vella S; Giuliano M
    J Antimicrob Chemother; 2014 Mar; 69(3):749-52. PubMed ID: 24135952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali.
    Derache A; Traore O; Koita V; Sylla A; Tubiana R; Simon A; Canestri A; Carcelain G; Katlama C; Calvez V; Cisse M; Marcelin AG
    Antivir Ther; 2007; 12(1):123-9. PubMed ID: 17503757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance-associated mutations in HIV-1 among patients failing first-line antiretroviral therapy.
    Saini S; Bhalla P; Gautam H; Baveja UK; Pasha ST; Dewan R
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(3):203-9. PubMed ID: 21990611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reliability at the lower limits of HIV-1 RNA quantification in clinical samples: a comparison of RT-PCR versus bDNA assays.
    Lubelchek RJ; Max B; Sandusky CJ; Hota B; Barker DE
    PLoS One; 2009 Jun; 4(6):e6008. PubMed ID: 19547711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.
    Cardoso LP; Queiroz BB; Stefani MM
    J Clin Virol; 2009 Oct; 46(2):134-9. PubMed ID: 19682948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT.
    Swanson P; de Mendoza C; Joshi Y; Golden A; Hodinka RL; Soriano V; Devare SG; Hackett J
    J Clin Microbiol; 2005 Aug; 43(8):3860-8. PubMed ID: 16081923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short communication: east meets west: a description of HIV-1 drug resistance mutation patterns of patients failing first line therapy in PEPFAR clinics from Uganda and Nigeria.
    Crawford KW; Wakabi S; Kibuuka H; Magala F; Keshinro B; Okoye I; Akintunde E; Hamm TE
    AIDS Res Hum Retroviruses; 2014 Aug; 30(8):796-9. PubMed ID: 24798614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the Quantiplex version 3.0 assay and a sensitized Amplicor monitor assay for measurement of human immunodeficiency virus type 1 RNA levels in plasma samples.
    Highbarger HC; Alvord WG; Jiang MK; Shah AS; Metcalf JA; Lane HC; Dewar RL
    J Clin Microbiol; 1999 Nov; 37(11):3612-4. PubMed ID: 10523562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
    Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
    HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early diagnosis of paediatric HIV-1 infection among African breast-fed children using a quantitative plasma HIV RNA assay.
    Rouet F; Montcho C; Rouzioux C; Leroy V; Msellati P; Kottan JB; You B; Viho I; Dabis F;
    AIDS; 2001 Sep; 15(14):1849-56. PubMed ID: 11579248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of effect of compartmentalized drug resistance mutations on HIV-1 pol divergence in antiretroviral-experienced women.
    Kelley CF; Sullivan ST; Lennox JL; Evans-Strickfaden T; Hart CE
    AIDS; 2010 Jun; 24(9):1361-6. PubMed ID: 20389234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of three different commercial procedures for quantifying human immunodeficiency virus type-1 RNA levels.
    Aschbacher R; Monari P; Lolli S; Donzelli C; Colangeli V; Vignoli M; Ramazzotti E; Furlini G; Re MC
    New Microbiol; 1999 Jan; 22(1):1-9. PubMed ID: 10190111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004.
    Pillay V; Ledwaba J; Hunt G; Rakgotho M; Singh B; Makubalo L; Bennett DE; Puren A; Morris L
    Antivir Ther; 2008; 13 Suppl 2():101-7. PubMed ID: 18575198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative evaluation between real time Roche COBas TAQMAN 48 HCV and bDNA Bayer Versant HCV 3.0.
    Giraldi C; Noto A; Tenuta R; Greco F; Perugini D; Spadafora M; Bianco AM; Savino O; Natale A
    New Microbiol; 2006 Oct; 29(4):243-50. PubMed ID: 17201090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
    Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
    J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical and virological correlation between the cerebrospinal fluid and blood of HIV-infected children].
    Sáez-Llorens X; Castrejón de Wong MC; Castaño E; de Suman O; Báez de Ulloa C; Redondo W; Espino M
    Rev Med Panama; 2001; 26():13-8. PubMed ID: 16161718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
    Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
    AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid detection of drug resistant HIV -1 to reverse transcriptase and protease inhibitors in HIV-infected patients receiving highly active antiretroviral therapies.
    Yu M; Kabat W; Wang J
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2000 Dec; 14(4):325-9. PubMed ID: 11471017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.